InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: vinmantoo post# 268993

Monday, 07/25/2016 10:48:40 PM

Monday, July 25, 2016 10:48:40 PM

Post# of 345677
Vinmantoo, you ever think about someone who already has the fast building boat load of data that PS Targeting will be an absolute requirement for the most optimal (combo treatment..) immuno-oncology SOC's and that this entity is just closing in as other Big Pharmas are continuing to spend Billions to try to catch up to IO 2.0?

I mean wouldn't that be the best hand to play this out..... to watch ones competitors spend Billions... upon Billions.... and KNOW they are falling apart once the time is right?

I think of the craziest things at times but imagine the Billions being spent that could be spent trying to buy a piece or just a small piece of PS Targeting/Peregrine ? : )

WHO knows, Peregrine just may become much more expensive one of these days

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News